RT Journal Article
T1 Roadmap and strategy for overcoming infusion reactions to nanomedicines
A1 Szebeni, Janos
A1 Simberg, Dmitri
A1 González Fernández, Maria Africa
A1 Barenholz, Yechezkel
A1 Dobrovolskaia, Marina A
K1 2412.05 Hipersensibilidad
AB Infusion reactions (IRs) are complex, immune-mediated side effects that mainly occur within minutes to hours of receiving a therapeutic dose of intravenously administered pharmaceutical products. These products are diverse and include both traditional pharmaceuticals (for example biological agents and small molecules) and new ones (for example nanotechnology-based products). Although IRs are not unique to nanomedicines, they represent a hurdle for the translation of nanotechnology-based drug products. This Perspective offers a big picture of the pharmaceutical field and examines current understanding of mechanisms responsible for IRs to nanomedicines. We outline outstanding questions, review currently available experimental evidence to provide some answers and highlight the gaps. We review advantages and limitations of the in vitro tests and animal models used for studying IRs to nanomedicines. Finally, we propose a roadmap to improve current understanding, and we recommend a strategy for overcoming the problem.
PB Nature Nanotechnology
SN 17483387
YR 2018
FD 2018-10-22
LK http://hdl.handle.net/11093/6342
UL http://hdl.handle.net/11093/6342
LA eng
NO Nature Nanotechnology, 13(12): 1100-1108 (2018)
NO National Cancer Institute
DS Investigo
RD 17-sep-2024